Close Menu


Advances in quantitative proteomics have great potential to improve cancer research and treatment by uncovering and validating novel drug targets, helping to understand drug mechanisms of action, and searching for new diagnostic, prognostic, or predictive biomarkers. 

Several examples of this innovation were on display at the recent American Association for Cancer Research Virtual Annual Meeting, where Biognosys published seven posters highlighting the utility of its next-generation proteomics platform in oncology.

Michiel Weber, Senior Bioinformatician at DDL (left), and A. Sinan Yavuz, PhD, Senior Bioinformatics Scientist, Seven Bridges (right)

Researchers worldwide are racing to address COVID-19, working on diagnostics, therapies, and vaccines to control the virus. To support these efforts, DDL Diagnostic Laboratory is developing faster ways to identify viral genomic variants – work that was accelerated by a collaboration with bioinformatics provider Seven Bridges.


A recent study, commissioned by ATCC, sheds new light on the challenges of research reproducibility. Pressure to publish, inadequate study design, and bias toward publishing positive results are all major contributors to the problem. Fortunately, identifying these issues is an important step towards improving them. To some degree, this is a cultural issue within the scientific community, and an attitudinal shift is necessary to solve it.

The Chan Zuckerberg Biohub is working with California's health department to sequence viral samples from COVID-19 patients to trace viral introductions, according to the San Francisco Chronicle.

Despite differences in their migration habits, eastern and western monarch butterflies are genetically similar, according to a study in Molecular Ecology.

The UK is implementing COVID-19 testing with a 90-minute turnaround time.

In PLOS this week: identification of fungal species in subcutaneous infections, sequencing of Campylobacter found in raw meat from retail stores, and more.